Regression of Atherosclerosis: Insights from Animal and Clinical Studies

Background: Based on studies that date back to the 1920s, regression and stabilization of atherosclerosis in humans has gone from just a dream to one that is achievable. Review of the literature indicates that the successful attempts at regression generally applied robust measures to improve plasma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Jonathan E. Feig
Formato:	article
Lenguaje:	EN
Publicado:	Ubiquity Press 2014
Materias:	atherosclerosis CCR7 HDL macrophages regression Infectious and parasitic diseases RC109-216 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/11c9ad3c925b426f943e823a2cba8faa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:11c9ad3c925b426f943e823a2cba8faa
record_format	dspace
spelling	oai:doaj.org-article:11c9ad3c925b426f943e823a2cba8faa2021-12-02T11:13:41ZRegression of Atherosclerosis: Insights from Animal and Clinical Studies2214-999610.1016/j.aogh.2013.12.001https://doaj.org/article/11c9ad3c925b426f943e823a2cba8faa2014-04-01T00:00:00Zhttps://annalsofglobalhealth.org/articles/51https://doaj.org/toc/2214-9996Background: Based on studies that date back to the 1920s, regression and stabilization of atherosclerosis in humans has gone from just a dream to one that is achievable. Review of the literature indicates that the successful attempts at regression generally applied robust measures to improve plasma lipoprotein profiles. Examples include extensive lowering of plasma concentrations of atherogenic apolipoprotein B and enhancement of reverse cholesterol transport from atheromata to the liver. Findings: Possible mechanisms responsible for lesion shrinkage include decreased retention of atherogenic apolipoprotein B within the arterial wall, efflux of cholesterol and other toxic lipids from plaques, emigration of lesional foam cells out of the arterial wall, and influx of healthy phagocytes that remove necrotic debris as well as other components of the plaque. This review will highlight the role key players such as LXR, HDL and CCR7 have in mediating regression. Conclusion: Although much progress has been made, there are many unanswered questions. There is, therefore, a clear need for preclinical and clinical testing of new agents expected to facilitate atherosclerosis regression with the hope that additional mechanistic insights will allow further progress.Jonathan E. FeigUbiquity PressarticleatherosclerosisCCR7HDLmacrophagesregressionInfectious and parasitic diseasesRC109-216Public aspects of medicineRA1-1270ENAnnals of Global Health, Vol 80, Iss 1, Pp 13-23 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	atherosclerosis CCR7 HDL macrophages regression Infectious and parasitic diseases RC109-216 Public aspects of medicine RA1-1270
spellingShingle	atherosclerosis CCR7 HDL macrophages regression Infectious and parasitic diseases RC109-216 Public aspects of medicine RA1-1270 Jonathan E. Feig Regression of Atherosclerosis: Insights from Animal and Clinical Studies
description	Background: Based on studies that date back to the 1920s, regression and stabilization of atherosclerosis in humans has gone from just a dream to one that is achievable. Review of the literature indicates that the successful attempts at regression generally applied robust measures to improve plasma lipoprotein profiles. Examples include extensive lowering of plasma concentrations of atherogenic apolipoprotein B and enhancement of reverse cholesterol transport from atheromata to the liver. Findings: Possible mechanisms responsible for lesion shrinkage include decreased retention of atherogenic apolipoprotein B within the arterial wall, efflux of cholesterol and other toxic lipids from plaques, emigration of lesional foam cells out of the arterial wall, and influx of healthy phagocytes that remove necrotic debris as well as other components of the plaque. This review will highlight the role key players such as LXR, HDL and CCR7 have in mediating regression. Conclusion: Although much progress has been made, there are many unanswered questions. There is, therefore, a clear need for preclinical and clinical testing of new agents expected to facilitate atherosclerosis regression with the hope that additional mechanistic insights will allow further progress.
format	article
author	Jonathan E. Feig
author_facet	Jonathan E. Feig
author_sort	Jonathan E. Feig
title	Regression of Atherosclerosis: Insights from Animal and Clinical Studies
title_short	Regression of Atherosclerosis: Insights from Animal and Clinical Studies
title_full	Regression of Atherosclerosis: Insights from Animal and Clinical Studies
title_fullStr	Regression of Atherosclerosis: Insights from Animal and Clinical Studies
title_full_unstemmed	Regression of Atherosclerosis: Insights from Animal and Clinical Studies
title_sort	regression of atherosclerosis: insights from animal and clinical studies
publisher	Ubiquity Press
publishDate	2014
url	https://doaj.org/article/11c9ad3c925b426f943e823a2cba8faa
work_keys_str_mv	AT jonathanefeig regressionofatherosclerosisinsightsfromanimalandclinicalstudies
_version_	1718396097948286976

Regression of Atherosclerosis: Insights from Animal and Clinical Studies

Ejemplares similares